allopregnanolone
AssetAlso called LPCN 1154A, Brexanolone, SAGE-547, SGE-102
Positively modulates GABA-A receptors, enhancing inhibitory neurotransmission.
- Stage
- Approved
- Modality
- Small molecule
- Target
- GABRA5
- 7
- Indications
- 20
- Trials
- 3
- Developers
Indications
8No named disease
Approved, accessdata.fda.gov, Nov 2, 2026
Post partum depression
Phase 3, Completed, NCT03665038, clinicaltrials.gov, Nov 2, 2026
Postpartum depression
Phase 3, Completed, NCT05059600, clinicaltrials.gov, Nov 2, 2026
5 more
In the full profile
- Target and mechanism16
- Owner and partners3
- Trials20
- Evidence for its targets8
- Competitors12
- Signals4
Every asset’s record: target, stage, trials and the evidence behind it.